Michael Gelband’s GSK GSK Stock Holding History

Michael Gelband’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-19,691	Closed	-$850K	–	1736
2025 Q3	$850K	Buy	+19,691	New	+$769K	0.01%	1013
2024 Q2	–	Sell	-311,337	Closed	-$13.3M	–	1693
2024 Q1	$13.3M	Buy	311,337 +74,528	+31%	+$3.07M	0.1%	163
2023 Q4	$8.78M	Sell	236,809 -62,488	-21%	-$2.24M	0.06%	224
2023 Q3	$10.8M	Buy	299,297 +281,082	+1,543%	+$9.98M	0.1%	203
2023 Q2	$649K	Buy	+18,215	New	+$653K	0.01%	1260
2023 Q1	–	Sell	-280,187	Closed	-$9.85M	–	1898
2022 Q4	$9.85M	Buy	280,187 +30,029	+12%	+$1M	0.14%	171
2022 Q3	$7.36M	Buy	250,158 +112,632	+82%	+$4.27M	0.1%	285
2022 Q2	$7.48M	Buy	137,526 +113,010	+461%	+$6.24M	0.09%	272
2022 Q1	$1.33M	Sell	24,516 -163	-0.7%	-$8.85K	0.02%	980
2021 Q4	$1.36M	Sell	24,679 -7,321	-23%	-$381K	0.01%	920
2021 Q3	$1.53M	Sell	32,000 -12,462	-28%	-$626K	0.02%	844
2021 Q2	$2.21M	Buy	+44,462	New	+$2.14M	0.02%	637
2021 Q1	–	Sell	-49,346	Closed	-$2.27M	–	2297
2020 Q4	$2.27M	Buy	49,346 +38,552	+357%	+$1.77M	0.02%	498
2020 Q3	$508K	Buy	+10,794	New	+$541K	0.01%	1008
2019 Q3	–	Sell	-5,040	Closed	-$252K	–	1450
2019 Q2	$252K	Sell	5,040 -10,500	-68%	-$527K	0.01%	786
2019 Q1	$812K	Buy	+15,540	New	+$777K	0.06%	226

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Michael Gelband's GSK Position: Q4 2025 in Review

Michael Gelband sold out of GSK (GSK) in Q4 2025, closing a stake of 19,691 shares — an estimated $850K sold.

Michael Gelband first reported a position in GSK in Q1 2019 and held it in 16 quarters. The position peaked at $13.3M in Q1 2024. 996 funds tracked by Wall St. Rank hold GSK as of Q4 2025.

Michael Gelband reported no remaining GSK position as of Q4 2025 after selling out during the quarter.
Michael Gelband sold 19,691 GSK shares in Q4 2025, an estimated $850K.
Michael Gelband first reported a position in GSK in Q1 2019 and held it in 16 quarters.
Michael Gelband's GSK position peaked at $13.3M in Q1 2024.
996 funds tracked by Wall St. Rank held GSK as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.